M&A / Deals UCB to purchase Neurona and NRTX-1001 for $1.15bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.M&A / DealsNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: MSD secures EC approval for Enflonsia to prevent infant RSV infectionNext: Trump backs psychedelics for mental health in new executive order Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
